Conformal Medical Closes Out Huge Round of Investment with Record-Breaking $35 Million Series D

Conformal Medical, Inc., a trailblazing medical device company, has achieved a major milestone with the successful completion of its latest Series D funding round, having raised an impressive $35 million. This funding will propel the company to the next level as it continues to develop innovative left atrial appendage occlusion (LAAO) technology for use in medical procedures.

SPRIG Equity is committed to giving transformative medical technology companies the opportunity to make a difference in the world and improve human life. With the investment in Conformal Medical, SPRIG Equity is aiming to make strides in the Left Atrial Appendage Occlusion market, a critical point of interest for the big players in the medical technology industry. According to Managing Partner, Evan Norton, this is the perfect way to further innovate and open new pathways for progress.

Incube Labs, a company dedicated to providing revolutionary treatments to reduce the risk of stroke in patients with non-valvular atrial fibrillation, has secured a highly successful round of funding to mark the progress and achievements it has made since its last round. At the center of these accomplishments is the initiation of the CONFORM Clinical Trial, which will evaluate the safety and effectiveness of their CLAAS® System compared to other LAAO devices on the market.

If successful, this study could potentially pave the way for U.S. Food and Drug Administration pre-market approval, further expanding the treatment options available to Afib patients without the need for anticoagulants.

Conformal Medical is delighted to have SPRIG Equity join their rapidly expanding investor base as they move forward with bringing the innovative CLAAS System to the rapidly growing LAAO market in the United States. With the Series D funding, the company will be able to complete enrollment in the CONFORM trial, drive iterative development projects, and broaden the clinical experience of the CLAAS System in additional regions. “We are honored to have such strong support as we work to bring this revolutionary system to the market and truly unlock its potential,” remarked CEO James Reinstein.

Conformal Medical is revolutionizing the treatment of Left Atrial Appendage (LAA) structural heart disease with their proprietary CLAAS technology. This cutting-edge foam-based architecture is designed to make the process simpler than ever with only two sizes, allowing off-axis positioning and a more uniform seal.

Furthermore, it could eliminate the need for procedural transesophageal echocardiogram and allow physicians to perform the procedure using only conscious sedation. With such revolutionary advancements, Conformal Medical is conducting clinical trials to prove the CLAAS implant’s safety profile and clinical efficacy in order to transform the way structural heart diseases are treated.

About Conformal Medical

Founded in 2016, Conformal Medical, Inc. is revolutionizing stroke prevention for patients with non-valvular Afib. Their proprietary technology enables a same day, single operator procedure for Left Atrial Appendage Occlusion (LAAO) – drastically streamlining the process and enhancing the safety of the procedure. With their ground-breaking device, Conformal Medical, Inc. is on a mission to rid the world of stroke.

About SPRIG Equity

SPRIG Equity is a growth equity and late-stage venture capital firm dedicated to improving patient outcomes by partnering with best-in-class teams and advancing medical technologies.

Leave a Comment